GSK plc (GSK) vs Pfizer Inc. (PFE)
GSK leads on 11 of 16 compared metrics.
A side-by-side comparison of GSK plc and Pfizer Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 24, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
GSK
GSK plc
$51.35HealthcareDelayed quote: Jul 24, 2026, 4:00 PM EDT
PFE
Pfizer Inc.
$24.54HealthcareAt close: Jul 24, 2026, 4:00 PM ET
Total return — GSK vs PFE
growth of $100 · dividends reinvested · last 30yGSK +576.1%PFE +528.5%GSK compounded faster
GSK PFE
GSK vs PFE: by the numbers
- •PFE is the larger company ($139.86B vs $103.60B market cap).
- •GSK trades at the lower earnings multiple (11.36 vs 18.73 P/E).
- •GSK converts more revenue to profit (17.76% vs 11.83% net margin).
- •PFE grew revenue faster over the past five years (8.22% vs 0.63% CAGR).
- •PFE pays the higher dividend yield (7.01% vs 3.50%).
Which is better, GSK or PFE?
Metric tally: GSK 11 · PFE 5It depends on what you're optimizing for:
ValueGSK(lower P/E)
GrowthPFE(faster 5Y revenue CAGR)
IncomePFE(higher dividend yield)
QualityGSK(higher ROIC)
Metrics side by side
Valuation
| Metric | GSK | PFE |
|---|---|---|
| P/E ratio | 11.36● | 18.73 |
| Forward P/E | 14.35 | 8.34● |
| P/S ratio | 2.37 | 2.22● |
| P/B ratio | 3.36 | 1.56● |
| PEG ratio | 0.02 | — |
| EV / EBITDA | 8.47● | 9.68 |
| FCF yield | 8.05%● | 6.74% |
Profitability
| Metric | GSK | PFE |
|---|---|---|
| Gross margin | 72.67%● | 69.35% |
| Operating margin | 25.65%● | 23.45% |
| Net margin | 17.76%● | 11.83% |
| ROE | 25.19%● | 8.31% |
| ROIC | 16.61%● | 8.84% |
Dividends
| Metric | GSK | PFE |
|---|---|---|
| Dividend yield | 3.50% | 7.01%● |
| Payout ratio | 23.66% | 126.47% |
Growth (annualized)
| Metric | GSK | PFE |
|---|---|---|
| Revenue CAGR (5Y) | 0.63% | 8.22%● |
| EPS CAGR (5Y) | 14.05%● | -3.78% |
| FCF CAGR (5Y) | -0.35%● | -3.79% |
| Total return CAGR (5Y) | 9.84%● | -4.97% |
Frequently asked
- Which is better, GSK or PFE?
- It depends on your goal. value: GSK (lower P/E); growth: PFE (faster 5Y revenue CAGR); income: PFE (higher dividend yield); quality: GSK (higher ROIC). Across all compared metrics, GSK leads 11 to 5.
- Is GSK or PFE cheaper?
- On trailing earnings, GSK is cheaper: GSK trades at a 11.36 P/E and PFE at 18.73.
- Which has grown faster, GSK or PFE?
- Over the past five years, PFE grew revenue faster — GSK at a 0.63% CAGR versus PFE at 8.22%.
- Does GSK or PFE pay a bigger dividend?
- GSK yields 3.50% and PFE yields 7.01% based on trailing dividends and the latest price.
- Is GSK or PFE more profitable?
- GSK runs the higher net margin — GSK at 17.76% versus PFE at 11.83%.
- Which has been the better investment, GSK or PFE?
- Over the past 10-year, GSK delivered the higher annualized total return — GSK at 6.48% versus PFE at 1.23%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
GSK P/E ratioPfizer P/E ratioGSK dividend yieldPfizer dividend yieldGSK ROEPfizer ROEGSK operating marginPfizer operating marginGSK revenue growthPfizer revenue growthGSK free cash flowPfizer free cash flow
GSK & Pfizer appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 24, 2026.